Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine timetable plus radiotherapy as adjuvant therapy in rectal cancer
2005-003676-38Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Apr 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in rectal cancer, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoints: Safety (grade 3/4 diarrhea), Safety (grade 3/4 proctitis) and 1 more. Started Apr 2007; status: completed.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2005-003676-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003676-38.